Quest Diagnostics (DGX) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenues reached $2.62 billion, up 14.5% year-over-year, with organic growth of 4.8%–5%.

• Full-year 2024 revenues were $9.87 billion, a 6.7% increase, with about 3% organic growth.

• Completed eight acquisitions in 2024, including LifeLabs in Canada and four U.S. hospital outreach labs, expanding advanced diagnostics and market reach.

• Investments in automation and AI improved quality, customer experience, and productivity, meeting annual 3% cost savings and productivity targets.

• Employee retention improved significantly, strengthening workforce stability.

Financial highlights

• Q4 consolidated revenues were $2.62 billion (+14.5% YoY); full year: $9.87 billion (+6.7% YoY).

• Diagnostic information services revenues rose 15.1% in Q4, driven by acquisitions and growth in physician and hospital channels.

• Q4 reported operating income was $361 million (13.8% margin); adjusted operating income was $409 million (15.6% margin).

• Q4 reported EPS was $1.95; adjusted EPS was $2.23, impacted by higher interest expense and tax rate.

• Full-year 2024 cash from operations was $1.33 billion, up from $1.27 billion in 2023; capital expenditures were $425 million.

Outlook and guidance

• 2025 revenue guidance: $10.7–$10.85 billion, representing 8.4%–9.9% growth.

• 2025 reported EPS: $8.34–$8.59; adjusted EPS: $9.55–$9.80.

• 2025 organic revenue growth expected at ~3%, with additional growth from 2024 acquisitions.

• Operating margin expected to expand in 2025; net interest expense projected at ~$275 million.

• Cash from operations expected at ~$1.45 billion; capital expenditures at ~$500 million.